AP3 This associate program of PMS-ICBG will characterize the chemical diversity inherent in mollusk symbiotic bacteria. We have demonstrated that mollusks contain diverse symbiotic bacteria, including strains that are closely related to previously identified strains, but also very commonly to rare or unique types of strains that have otherwise resisted cultivation and that are not available in other culture collections. We have demonstrated that these strains provide a rich, privileged source of novel, biologically active natural products with potential in treating human diseases. The goal of this program is to isolate and purify biologically active components from these bacteria. In addition, we will determine which types of compounds are important to symbiosis, and we will follow up on potential pharmaceutical hits by discovering or synthesizing active analogs in a drug development strategy. Another critical aspect of AP3 is training. Our goal is to help MSI-UP become a globally known center for natural products chemistry. With the recent acquisition of chemical infrastructure, such as the first modern NMR and MS instrumentation in the country, and an excellent educational environment, MSI-UP is poised to make this leap, which will be greatly facilitated through carefully planned interactions in this PMS-ICBG. To achieve these goals, we plan to: 1) Prioritize bacterial samples for chemical and biological analysis; 2) Elucidate structures; 3) Provide training to aid the development of natural products chemistry at MSI-UP; 4) Optimize hits via chemical approaches.

Public Health Relevance

AP3 This associate program of the PMS-ICBG will provide extracts and purified compounds for analysis in our AP2 Symbiosis and AP4 Pharmacology programs. In turn, these compounds will be screened for their pharmaceutical potential in treating human health conditions that include, but are not limited to: neurological conditions, cancers, including pancreatic cancer and glioblastoma, pandrug-resistant bacterial infections, and infections by apicomplexan parasites.

Agency
National Institute of Health (NIH)
Institute
Fogarty International Center (FIC)
Type
Research Program--Cooperative Agreements (U19)
Project #
2U19TW008163-06
Application #
8783904
Study Section
Special Emphasis Panel (ZRG1-BCMB-H (50))
Project Start
Project End
Budget Start
2014-08-26
Budget End
2015-07-31
Support Year
6
Fiscal Year
2014
Total Cost
$127,001
Indirect Cost
$38,323
Name
Oregon Health and Science University
Department
Type
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239